Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTEST: Dalteparin for VTE Prophylaxis in Severe TBI
NCT03559114Phase 3Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Jul 2018
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dalteparin in venous thromboembolism (VTE), sponsored by Sunnybrook Health Sciences Centre. Started Jul 2018; status: recruiting.
02
Drugs
dalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03559114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559114.